Lakeshore Biopharma Co, LTD Schedule 13D activist filings

LakeShore Biopharma has finalized its merger agreement, becoming a privately held subsidiary with shareholders receiving $0.066 per share in cash.

LakeShore Biopharma Co., Ltd. announces an amendment to its merger agreement, reducing the per-share consideration and adjusting termination fees.

Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. have submitted a revised non-binding proposal to acquire LakeShore Biopharma Co., Ltd, significantly reducing the per-share merger consideration from US$0.90 to US$0.06 due to substantial arbitral awards.

The Buyer Group has determined that recent arbitral awards totaling approximately RMB 576.5 million constitute a material adverse effect, leading to their decision not to proceed with the merger on current terms.

LakeShore Biopharma Co., Ltd. announced a definitive merger agreement to be acquired by Oceanpine Skyline Inc. for $0.90 per ordinary share in cash, taking the company private.

A consortium of investors, including major shareholders, has proposed to acquire all outstanding shares of LakeShore Biopharma Co., Ltd. not already owned by them for $0.86 per share, aiming to take the company private.

A consortium including major shareholders proposes to acquire all outstanding shares of LakeShore Biopharma Co., Ltd for $0.86 per share in cash, aiming to take the company private.

Crystal Peak Investment Inc., along with its affiliates, has acquired a 51% beneficial ownership stake in LakeShore Biopharma Co., Ltd. through a $15 million private placement and subsequent warrant exercise.

Fung Ching Wong and Apex Prospect Limited's beneficial ownership in LakeShore Biopharma Co., Ltd. decreased to 23.9% due to the company's recent private placement, not from any share sales.